QuidelOrtho Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
$QDEL
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 14, 2024
(Exact name of Registrant as specified in its Charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices, including zip code)
(858 ) 552-1100
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |||||
| Emerging growth company | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ | ||||
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 14, 2024, QuidelOrtho Corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). The following are the final voting results on proposals considered and voted upon at the Annual Meeting, all of which are described in the Company's Proxy Statement filed with the Securities and Exchange Commission on April 2, 2024 (the “Proxy Statement”).
Proposal No. 1
The Company's stockholders elected ten individuals to the Company's Board of Directors (the “Board”) as set forth below:
| Name | Votes For | Votes Withheld | Broker Non-Votes | ||||||||
| Kenneth F. Buechler, Ph.D. | 55,493,739 | 3,467,830 | 4,262,897 | ||||||||
| Evelyn S. Dilsaver | 56,374,796 | 2,586,773 | 4,262,897 | ||||||||
| Edward L. Michael | 56,059,355 | 2,902,214 | 4,262,897 | ||||||||
| Mary Lake Polan, M.D., Ph.D., M.P.H. | 55,797,245 | 3,164,324 | 4,262,897 | ||||||||
| James R. Prutow | 56,160,513 | 2,801,056 | 4,262,897 | ||||||||
| Ann D. Rhoads | 55,550,591 | 3,410,978 | 4,262,897 | ||||||||
| Robert R. Schmidt | 56,104,590 | 2,856,979 | 4,262,897 | ||||||||
| Matthew W. Strobeck, Ph.D. | 56,372,260 | 2,589,309 | 4,262,897 | ||||||||
| Kenneth J. Widder, M.D. | 53,622,971 | 5,338,598 | 4,262,897 | ||||||||
| Joseph D. Wilkins Jr. | 55,630,405 | 3,331,164 | 4,262,897 | ||||||||
Proposal No. 2
The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers by the votes set forth in the table below:
| Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||||
| 54,888,387 | 3,194,023 | 879,159 | 4,262,897 | ||||||||
Proposal No. 3
The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's 2024 fiscal year by the votes set forth in the table below:
| Votes For | Votes Against | Abstentions | ||||||
| 61,334,670 | 1,022,808 | 866,988 | ||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 17, 2024
| QUIDELORTHO CORPORATION | ||||||||
| By: | /s/ Michelle A. Hodges | |||||||
| Name: | Michelle A. Hodges | |||||||
| Its: | Secretary | |||||||